Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept. — RESCUE  

Recalcitrant Wet Age-related Macular Degeneration Clinical Trial

Status Completed

Clinical Trial Summary

The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept. These subjects have demonstrated a sub-optimal therapeutic response to the previous therapies; therefore, the study aims to see if Ranibizumab may have a greater treatment effect.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Macular Degeneration
• Recalcitrant Wet Age-related Macular Degeneration

• NCT number: NCT01972763
• Study type: Interventional
• Source: Northern California Retina Vitreous Associates
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: October 2013
• Completion date: July 2018